E Fund Management Co., Ltd. Neurocrine Biosciences Inc Transaction History

E Fund Management Co., Ltd.

$1.93 Billion
Q3 2024

A detailed history of E Fund Management Co., Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 8,887 shares of NBIX stock, worth $1.12 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

8,887

Previous 7,319 21.42%

Holding current value

$1.12 Million

Previous $1.01 Million 1.59%

% of portfolio

0.05%

Previous 0.06%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $179,661 - $240,139	1,568 Added 21.42%	8,887 $1.02 Million
Q2 2024 Aug 12, 2024	BUY	$130.86 - $143.19 $550,397 - $602,257	4,206 Added 135.11%	7,319 $1.01 Million
Q1 2024 May 13, 2024	SELL	$130.4 - $143.74 $128,183 - $141,296	-983 Reduced 24.0%	3,113 $429,000
Q4 2023 Feb 06, 2024	SELL	$106.07 - $132.76 $9,440 - $11,815	-89 Reduced 2.13%	4,096 $539,000
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $56,223 - $70,025	-598 Reduced 12.5%	4,185 $471,000
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $67,326 - $78,862	752 Added 18.66%	4,783 $451,000
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $39,996 - $52,283	425 Added 11.79%	4,031 $408,000
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $92,526 - $110,161	-867 Reduced 19.38%	3,606 $431,000
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $15,645 - $18,327	-170 Reduced 3.66%	4,473 $475,000
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $124,144 - $163,914	1,638 Added 54.51%	4,643 $453,000
Q1 2022 May 12, 2022	BUY	$72.45 - $94.81 $114,253 - $149,515	1,577 Added 110.43%	3,005 $282,000
Q1 2021 May 12, 2021	BUY	$87.57 - $119.4 $125,049 - $170,503	1,428 New	1,428 $138,000

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.

Account

E Fund Management Co., Ltd. Neurocrine Biosciences Inc Transaction History